| Yang, Hui |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group | Ganzhou Hemay Pharmaceutical Co., Ltd | Moderate to Severe Ulcerative Colitis | 06/24 | 09/24 | | |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
